A prominent example is the stratification of epithelial ovarian cancer (EOC) patients with homologous recombination deficiency (HRD) characterized by mutations in DNA damage repair genes such as BRCA1/2 for treatment with PARP inhibitors. Here, PARP1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.